A draft Evidence Report published by ICER on 21 December 2022, compared ublituximab to other available multiple sclerosis disease modifying therapies (DMTs) for comparative effectiveness and value in reducing annualized relapse rate (ARR) and confirmed disability progression (CDP) in relapsing remitting multiple sclerosis (RRMS).

Conclusions

• Ublituximab was judged as better or comparable to oral DMTs in reducing ARR and CDP in RRMS
• Based on head-to-head trial data, ublituximab provides a small net health benefit over teriflunomide
• The net health benefit of ublituximab could not be compared to other monoclonal DMTs because of insufficient data
• Based on comparative effectiveness and value, ICER's suggested price for ublituximab, natalizumab, ofatumumab, and ocrelizumab should be between $16,500- $34,900 per year.

​

ICER Report: Oral and MAb Treatments for RRMS

​

ICER Report: Oral and MAb Treatments for RRMS

​

Source: Oral and Monoclonal Antibody Treatments for Relapsing Forms of Multiple Sclerosis: Effectiveness and Value. Evidence Report. Institute for Clinical and Economic Review. December 21, 2022

Related posts: List of DMTs; moderate- vs high-efficacy DMTs; Kesimpta vs teriflunomide (Aubagio)